Author:
Esber Nathalie,Cherbonnier Clément,Resche-Rigon Michèle,Hamze Abdallah,Alami Mouad,Fagart Jérôme,Loosfelt Hugues,Lombès Marc,Chabbert-Buffet Nathalie
Funder
Inserm
université Paris Sud
Agence Nationale de la Recherche
Ligue Contre le Cancer
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Endocrine and Autonomic Systems,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism
Reference61 articles.
1. Aparicio S, Hidalgo M, Kung AL (2015) Examining the utility of patient-derived xenograft mouse models. Nature Reviews Cancer 15(5):311–316. doi:10.1038/nrc3944
2. Bakker GH, Setyono-Han B, Henkelman MS, de Jong FH, Lamberts SW, van der Schoot P, Klijn JG (1987) Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors. Cancer Treatment Reports 71(11):1021–1027
3. Bissery MC, Chabot GG (1991) History and new development of screening and evaluation methods of anticancer drugs used in vivo and in vitro. Bull Cancer 78(7):587–602
4. Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU et al (2008) Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst 100(16):1179–1183. doi:10.1093/jnci/djn233
5. Brisken C (2013) Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. Nature Reviews Cancer 13(6):385–396. doi:10.1038/nrc3518
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献